Specific targeting of EVs involved in a bidirectional cross-talk between CLL cells and the bone marrow microenvironment, particularly those containing Myc, would be of great therapeutic interest to impede CLL cell growth, progression, and resistance to therapy. Here, MYC is linked to B-cell chronic lymphocytic leukemia.